海马尾部体积增大可预测抑郁症状态及抗抑郁药缓解
研究基于iSPOT-D,对202例非精神病性MDD门诊患者(HRSD17≥16)与68名性别匹配健康对照进行治疗前MRI,自动测量海马亚区体积。控制年龄与全脑体积后,MDD组海马尾部体积大于对照,且海马尾部体积较大与8周开放标签抗抑郁药治疗后的临床缓解正相关,独立于全海马体积、全脑体积和年龄。
要点
- MDD患者海马尾部体积大于性别匹配健康对照。
- 海马尾部体积较大与抗抑郁药8周临床缓解正相关。
- 该关联独立于全海马体积、全脑体积和年龄。
核心结论
- 海马尾部体积与MDD诊断及抗抑郁药治疗缓解相关,可能作为治疗敏感性生物标志物。
研究设计与样本
- 国际iSPOT-D研究,202例符合DSM-IV的非精神病性MDD门诊患者(HRSD17≥16)与68名性别匹配健康对照,治疗前MRI自动测量海马亚区及全脑体积。
主要发现
- 控制年龄和全脑体积后,MDD组海马尾部体积大于对照组。
- 海马尾部体积较大与临床缓解正相关,独立于全海马体积、全脑体积和年龄。
关键数值与推荐
- 缓解定义为8周随机开放标签艾司西酞普兰、舍曲林或文拉法辛缓释剂治疗后HRSD17≤7。
- MDD入组标准为DSM-IV诊断且HRSD17≥16。
临床怎么用
- 海马尾部体积或有助于提示MDD患者对抗抑郁药的敏感性,但尚需进一步验证后方可用于临床决策。
局限性
- 原文摘要未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Studies of patients with major depressive disorder (MDD) have consistently reported reduced hippocampal volumes; however, the exact pattern of these volume changes in specific anatomical subfields and their functional significance is unclear. We sought to clarify the relationship between hippocampal tail volumes and (i) a diagnosis of MDD, and (ii) clinical remission to anti-depressant medications (ADMs). Outpatients with nonpsychotic MDD (n=202) based on DSM-IV criteria and a 17-item Hamilton Rating Scale for Depression (HRSD17) score ⩾16 underwent pretreatment magnetic resonance imaging as part of the international Study to Predict Optimized Treatment for Depression (iSPOT-D). Gender-matched healthy controls (n=68) also underwent MRI scanning. An automated pipeline was used to objectively measure hippocampal subfield and whole brain volumes. Remission was defined as an HRSD17 of ⩽7 following 8 weeks of randomized open-label treatment ADMs: escitalopram, sertraline or venlafaxine-extended release. After controlling for age and total brain volume, hippocampal tail volume was larger in the MDD cohort compared to control subjects. Larger hippocampal tail volume was positively related to clinical remission, independent of total hippocampal volume, total brain volume and age. These data provide convergent evidence of the importance of the hippocampus in the development or treatment of MDD. Hippocampal tail volume is proposed as a potentially useful biomarker of sensitivity to ADM treatment.
引用
- Maller JJ, Broadhouse K, Rush AJ, et al. Increased hippocampal tail volume predicts depression status and remission to anti-depressant medications in major depression. Mol Psychiatry. 2017. PMID: 29133948. doi:10.1038/mp.2017.224
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。